Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.
source: pixabay.com
For twenty-five years Women of Influence has focused on empowering and helping to advance women in the workforce. Maayan Ziv, a Canadian tech entrepreneur, disability advocate, and voted one…
Continue Reading
An Interview With the Founder of AccessNow: COVID-19 and the Disabled Community
source: pixabay.com
Results of a Phase III study of CC-486 (oral form of azacitidine) showed a significant improvement for older patients who had been transfusion dependent. The results were favorable when…
Continue Reading
CC-486 Improves Myelodysplastic Syndromes Patient’s Transfusion Independence But With Significant Adverse Reactions
source: pixabay.com
According to the American Cancer Society, there are approximately 1.7 million people in the U.S. diagnosed with cancer each year. About forty percent of these cases may be eligible…
Continue Reading
Early Intervention is Needed to Meet the Challenge of Immune-Related Adverse Events
source: pixabay.com
Orphan drug designations are granted by the FDA to drugs and biologics that are developed for the treatment of rare diseases. According to a recent article in Biospace, Oncternal…
Continue Reading
The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
source: pixabay.com
While the world is waiting for a vaccine to prevent, mitigate, or cure COVID-19, the investigational drug remdesivir continues to show promise. The FDA recently gave it Emergency Use…
Continue Reading
Remdesivir Showed 74.4% Recovery for COVID-19 Within Fourteen Days of Hospitalization
source: pixabay.com
The National Institutes of Health (NIH) recently published the results of studies based on a controversy that has remained unresolved for decades. The ISCHEMIA study is not only the…
Continue Reading
ICYMI: Studies Compare Procedures for Reducing Risk of Heart Attacks
source: pixabay.com
According to an article in Globe NewsWire, Onconova Therapeutics, a biopharmaceutical company currently focusing on myelodysplastic syndromes, recently announced results of its Phase 1 study of oral rigosertib in…
Continue Reading
ICYMI: Experimental MDS Combination Shows Promise
source: pixabay.com
Alaina Johns, a Philadelphia based freelance writer, wears two hats. One hat as editor-in-chief of the Broad Street Review, and the other as a patient with several chronic illnesses.…
Continue Reading
Chronic Illness and Black Lives Matter: You Can Make a Difference
source: pixabay.com
Patients with inoperable or metastasized neuroendocrine tumors (NETs) may now benefit from recently FDA approved peptide receptor radionuclide therapy (PRRT) according to a recent article in MedPage Today. The…
Continue Reading
FDA Approves PRRT to Treat Neuroendocrine Tumors
source: pixabay.com
Medtronic’s Percept is the fourth deep brain stimulation (DBS) system that has been approved by the FDA according to a recent article in Parkinson’s News Today. The unique feature…
Continue Reading
ICYMI: FDA Approves the Fourth Deep Brain Stimulator System for Parkinson’s With BrainSense Technology
According to a recent article in EurekaAlert, researchers at the University of Boston recently published their new study investigating ROBO2. The ROBO2 signaling pathway has emerged as a therapeutic…
Continue Reading
High ROBO2 Protein Levels in Chronic Kidney Disease Point to a New Therapeutic Target
Well-known characteristics of aging are the loss of skeletal muscle mass and a general decline in all of the organs in the body. The speed of decline coincides with the…
Continue Reading
Ten Preclinical Studies and the Potential to Improve the Aging Process
source: pixabay.com
After forty years of research to counter or cure acute myeloid leukemia and other blood cancers, a few years ago the medical community exploded with eight new cancer drugs.…
Continue Reading
$6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments
source: pixabay.com
BioMed Central recently featured a pilot study conducted by a team at Japan’s Hitachi General Hospital department of critical care and emergency medicine. Their pilot study is based on…
Continue Reading
Researchers Have Discovered a Biomarker to Evaluate Critical Illness Myopathy
source: pixabay.com
Parkinson’s News Today recently published an article containing new information about biomarkers in Alzheimer’s disease that can be linked to the early stages of Parkinson’s disease. Many people with…
Continue Reading
Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
Generating neurons is only one of many goals that have so far escaped scientists worldwide. According to an article in Yahoo, the lead author of a new study in the…
Continue Reading
Accidental Scientific Discovery Brings Cure to Mice with Parkinson’s Disease
According to a recent article in Parkinson’s News Today, researchers at the UCSF Weill Institute discovered that disturbances in circadian rhythm increased a person’s risk of Parkinson's disease threefold. Circadian…
Continue Reading
Researchers Find that Disturbances in the Body’s Internal Clock Increase the Risk of Parkinson’s Disease Threefold
Scientists from the Universities of Edinburgh and Cambridge in collaboration with a research center in Germany have analyzed a DNA-damaging chemical that has given scientists a better understanding of the…
Continue Reading
This Study Improved Scientists’ Understanding of Cancer’s Complexity
Sound Pharmaceuticals announced the first-ever Phase III clinical trial protocol for Meniere’s disease to be approved by the FDA. Meniere’s disease (MD) is a neurotologic disorder that involves tinnitus (ringing…
Continue Reading
New Meniere’s Disease Treatment Has FDA Approval to Advance to a Phase III Trial
According to a recent article in The Guardian, funding received from the NIHR and Medical Research Council will facilitate the launch of the largest genetic study of chronic fatigue syndrome…
Continue Reading
The World’s Largest Genetic Study of Chronic Fatigue Syndrome is About to be Launched
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Administration (FDA) has granted…
Continue Reading
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
Why are most people able to tolerate cat’s hair while some people have severe reactions to the ubiquitous and practically invisible dust mites? A recent SciTech Daily article followed La…
Continue Reading
Scientists Find New Pathway Leading to Less Inflammation in Asthma and Other Allergic Diseases
source: pixabay.com
COVID-19 has now taken hold in over one hundred eighty countries. According to a recent article in The Lancet, in May of 2020, the United States reported the highest…
Continue Reading
International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
Osteoporosis is known to affect over two hundred million people worldwide. According to a recent article in the Endocrinology Advisor, fractures of the spine or hip due to reduced…
Continue Reading
Is It Safe to Take a Break From Your Osteoporosis Medication?
source: pixabay.com
Earlier this year, The Leukemia & Lymphoma Society hosted a presentation by Dr. Eunice Wang, Clinical Leukemia Service, Professor of Oncology, Roswell Park Comprehensive Cancer Center. Dr. Wang’s presentation…
Continue Reading
Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia